SESSION TITLE: Critical Care in the ICU
SESSION TYPE: Original Investigation Poster Discussion
PRESENTED ON: Monday, October 24, 2016 at 12:00 PM - 01:30 PM
PURPOSE: Dexmedetomidine (DEX) is an alpha-2 adenoreceptor agonist which is increasingly being recognized as an alternative sedative in the critically ill. DEX provides sedation, anxiolysis, analgesia and attenuation of the stress response. We hypothesize that patients with a history of substance abuse would benefit from use of DEX. We studied patient characteristics and outcomes of all patients on DEX infusions and compared them based on their history of substance abuse.